Roche (ROG) Given a CHF 325 Price Target at Goldman Sachs Group
ROG has been the topic of several other reports. Deutsche Bank set a CHF 255 price objective on Roche and gave the stock a neutral rating in a report on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on Roche and gave the stock a neutral rating in a report on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a buy rating on shares of Roche in a report on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on Roche and gave the stock a neutral rating in a report on Friday, October 6th. Finally, Jefferies Group set a CHF 295 target price on Roche and gave the company a buy rating in a research report on Monday, October 16th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. Roche currently has a consensus rating of Hold and a consensus target price of CHF 261.84.
Shares of Roche (VTX ROG) remained flat at $CHF 241.70 during trading on Wednesday. The company had a trading volume of 1,440,000 shares, compared to its average volume of 1,670,000. Roche has a 52-week low of CHF 223.70 and a 52-week high of CHF 273.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.